PENTAX Medical secures CE mark approval for innovative AI-assisted polyp detector

PENTAX Medical, a division of the HOYA Group, announced that it has cleared CE mark for DISCOVERY™, an innovative Artificial Intelligence (AI) assisted polyp detector designed to support endoscopists in finding potential polyps during a colorectal examination.

PENTAX Medical secures CE mark approval for innovative AI-assisted polyp detector

DISCOVERY™ is the outcome of a close cooperation between PENTAX Medical research center located in Augsburg, Germany, and expert clinical partners from six of the leading medical institutions across the world. For this next generation development, a total of more than 120,000 files from approximately 300 clinical cases were used for the software training. By this, DISCOVERY™ is able to assist with the detection of potential polyps in real time.

The system is built in a flat monitor to provide a high usability as it can be used with any of PENTAX Medical video endoscopy systems to highlight potential polyps. The menu is self-explaining and uses an intuitive touchscreen interface.

"The benefits for the customers are outstanding. Our vision was to bring Artificial Intelligence into the operating room in the most user-friendly way. We wanted to give doctors the possibility to use this exciting new technology to strive for a better clinical outcome and maximize the patient care", Mr. Wolfgang Mayer, Managing Director. R & D, PENTAX Medical Augsburg mentioned.

PENTAX Medical is committed to continuously exploit the use of Artificial Intelligence in additional medical fields. By gradually enhancing the product line up, PENTAX Medical has dedicated themselves to leverage AI for the further support of customers and patients.

Prof Timo Rath, Professor of Endoscopy and Molecular Imaging, University of Erlangen, Nuremberg, Germany mentioned:

As endoscopists one of our major tasks is to reduce the incidence of colorectal cancer. I'm very confident that the DISCOVERY™ will translate into increasing our own Adenoma Detection Rate and therewith will contribute to reduce colorectal cancer mortality".

PENTAX Medical plan to launch in the first markets in spring 2020.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PENTAX Medical Company. (2020, January 10). PENTAX Medical secures CE mark approval for innovative AI-assisted polyp detector. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20200110/PENTAX-Medical-secures-CE-mark-approval-for-innovative-AI-assisted-polyp-detector.aspx.

  • MLA

    PENTAX Medical Company. "PENTAX Medical secures CE mark approval for innovative AI-assisted polyp detector". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20200110/PENTAX-Medical-secures-CE-mark-approval-for-innovative-AI-assisted-polyp-detector.aspx>.

  • Chicago

    PENTAX Medical Company. "PENTAX Medical secures CE mark approval for innovative AI-assisted polyp detector". News-Medical. https://www.news-medical.net/news/20200110/PENTAX-Medical-secures-CE-mark-approval-for-innovative-AI-assisted-polyp-detector.aspx. (accessed November 21, 2024).

  • Harvard

    PENTAX Medical Company. 2020. PENTAX Medical secures CE mark approval for innovative AI-assisted polyp detector. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20200110/PENTAX-Medical-secures-CE-mark-approval-for-innovative-AI-assisted-polyp-detector.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PENTAX Medical to support distribution of SMART's G-EYE technology across the EMEA market